“New Method” framework 2024 annual summary released in Norway

Norway has a national framework for introducing new health technologies within the specialist health service, known as the "New Methods". This framework mandates that all innovations undergo either a national or hospital-based health technology assessment (HTA) before receiving funding. Once the national HTA is completed, the four Regional Health Authorities (RHAs) make coverage decisions through the Decision Forum.

In 2024, the Decision Forum reviewed 109 methods, of which only one was non-pharmaceutical: Molecular gene profiling test (Oncotype DX), which received favorable coverage recommendations for certain clinical indications.

Additionally, the 2024 annual report includes statistics on proposals assessed by the Ordering Forum for “New Method”, progress on various improvement initiatives, the New Methods strategy, and ongoing efforts to integrate with the EU Health Technology Assessment Regulation (HTAR).

See the full details in Norwegian here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.